Jump to content
Invision Community
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE
META-99 SEARCH ENGINE             CONTACT US
Sign in to follow this  
davidtrump

Alzheimer's prevention trials

Recommended Posts

Alzheimer's prevention trials

The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Study

The A4 Study is examining the effectiveness of solanezumab, a drug targeting beta-amyloid, in 1,150 symptom-free volunteers whose positron emission tomography (PET) scans show abnormally high levels of beta-amyloid in the brain. High levels of beta-amyloid in the brain increase the risk for developing Alzheimer's disease. Researchers hope that early intervention in individuals at increased risk of developing Alzheimer's will prevent cognitive decline.

Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)

Mutations on three genes are known to cause a rare form of Alzheimer’s disease that accounts for less than 1 percent of cases. When a person has one of these mutations, he or she has a 95 to 100 percent chance of developing Alzheimer’s. DIAN-TU hopes to slow or stop the development of Alzheimer’s in these individuals with experimental drugs. Two drugs, gantenerumab and solanezumab, are currently being tested. Both are designed to help remove excess beta-amyloid in the brain. The brain changes of people with this form of Alzheimer’s are very similar to the brain changes of those with the more common sporadic form of Alzheimer’s disease. It’s possible that a drug that slows or stop Alzheimer’s in DIAN-TU participants will also slow or stop the in people living with, or who are at high risk of, sporadic Alzheimer’s.

The Alzheimer's Prevention Initiative (API)

API includes both the Autosomal Dominant Alzheimer's Disease (ADAD) trial and the Generation Study. Like DIAN-TU, the API tests therapies in people who have a gene mutation that causes Alzheimer’s, but who have not yet developed symptoms. Drugs that delay or prevent symptoms in people with genetic mutations for Alzheimer's may potentially delay or prevent symptoms in people with the brain changes of Alzheimer's who do not have these genetic mutations. The ADAD trial is studying the effects of crenezumab, an immune-based therapy. Crenezumab delivers antibodies against beta-amyloid in an effort to reduce the negative cognitive effects of excess beta-amyloid. The Generation Study includes cognitively healthy older adults who are at high risk of developing Alzheimer’s based on their age and having two copies of the Alzheimer’s risk gene APOE-e4. This study focuses on whether two investigational drugs — an active immunotherapy (CAD106) and a BACE inhibitor (CNP520) — can prevent or delay the onset of Alzheimer’s symptoms.

Participate in a clinical trial

If you are interested in participating in a current clinical trial, use Alzheimer's Association TrialMatch®, a free, easy-to-use clinical studies matching service that generates customized lists of studies based on user-provided information. A lack of volunteers for Alzheimer's clinical trials is one of the greatest obstacles slowing the progress of potential new treatments.

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  

×
×
  • Create New...